<DOC>
	<DOC>NCT02107430</DOC>
	<brief_summary>The purpose of this study is to determine whether DCVAC/PCa added after radical primary prostatectomy can improve PSA progression times within 5 years for patients with high risk localized Prostate Cancer.</brief_summary>
	<brief_title>Phase II Study of DCVAC/PCa After Primary Radiotherapy for Patients With High Risk Localized Prostate Cancer</brief_title>
	<detailed_description>Treatment post radical primary prostatectomy Treatment post standard radiotherapy</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Male 18 years and older Histologically confirmed localized prostate cancer of high risk or very high risk fulfilling at least one of the following: T3T4 stage or Gleason Score 810 or PSA level above 20 ng/ml Indication for prostate cancer radical radiotherapy Neoadjuvant androgen androgendeprivation therapy due to prostate cancer using Luteinizinghormonereleasing hormone (LHRH) analogues ongoing for at least two months and not longer than 12 months prior randomization Eastern Cooperative Oncology Group (ECOG) 02 Primary surgical treatment of prostate cancer Prior or ongoing chemotherapy for prostate cancer Participation in other clinical study or administration of other evaluated drug within 30 day prior screening Unresolved lasting obstruction of urinary system Other uncontrolled intercurrent illness Treatment with immunotherapy against Prostate Cancer Clinically significant cardiovascular disease History of primary immunodeficiency Active autoimmune disease requiring treatment</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Biological, Vaccine</keyword>
</DOC>